CEBPA and acute myeloid leukemia: The OS in AML is evaluated with a number of driver mutations as NPM1, CEBPA, FLT3-ITD, chromatin and RNA splicing genes, TP53 mutation, chromosomal aneuploidy all together with cytogenetic abnormalities and age.